J
Jennifer L. Ariazi
Researcher at GlaxoSmithKline
Publications - 8
Citations - 618
Jennifer L. Ariazi is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Hypoxia-inducible factors & Erythropoiesis. The author has an hindex of 5, co-authored 8 publications receiving 527 citations. Previous affiliations of Jennifer L. Ariazi include Fox Chase Cancer Center.
Papers
More filters
OtherDOI
Estrogen Receptors as Therapeutic Targets in Breast Cancer
TL;DR: The development of resistance to endocrine therapy remains a clinically important problem, and laboratory models based on human breast cancer cells grown as tumors in immune-compromised mice have led to important insights into this problem.
Journal ArticleDOI
Tunneling Nanotubes and Gap Junctions-Their Role in Long-Range Intercellular Communication during Development, Health, and Disease Conditions.
Jennifer L. Ariazi,Andrew B. Benowitz,Vern de Biasi,Monique L. den Boer,Stephanie Cherqui,Haifeng Cui,Nathalie Douillet,Eliseo A. Eugenin,Eliseo A. Eugenin,David Favre,Spencer Goodman,Karine Gousset,Dorit Hanein,David I. Israel,Shunsuke Kimura,Robert B. Kirkpatrick,Nastaran Z. Kuhn,Claire G. Jeong,Emil Lou,Robbie B. Mailliard,Stephen Maio,George Okafo,Matthias Osswald,Matthias Osswald,Jennifer Pasquier,Roel Polak,Gabriele Pradel,Bob de Rooij,Peter Schaeffer,Vytenis Arvydas Skeberdis,Ian F. Smith,Ahmad Tanveer,Niels Volkmann,Zhenhua Wu,Chiara Zurzolo +34 more
TL;DR: The combined data from numerous laboratories indicate that some TNT mediate a long-range gap junctional communication to coordinate metabolism and signaling, in relation to infectious, genetic, metabolic, cancer, and age-related diseases.
Journal ArticleDOI
Chronic inhibition of hypoxia-inducible factor prolyl 4-hydroxylase improves ventricular performance, remodeling, and vascularity after myocardial infarction in the rat.
Weike Bao,Pu Qin,Saul Needle,Connie L. Erickson-Miller,Kevin J. Duffy,Jennifer L. Ariazi,Shufang Zhao,Alan R. Olzinski,David J. Behm,G. C. Teg Pipes,Beat M. Jucker,Erding Hu,John J. Lepore,Robert N. Willette +13 more
TL;DR: Chronic post-myocardial infarction treatment with a selective HIF PHD inhibitor (GSK360A) exerts systemic and local effects by stabilizing HIF-1α signaling and improves long-term ventricular function, remodeling, and vascularity in a model of established ventricular dysfunction.
Journal ArticleDOI
Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor–Prolyl Hydroxylase Inhibitor for Anemia
Jennifer L. Ariazi,Kevin J. Duffy,David F. Adams,Duke M. Fitch,Lusong Luo,Melissa B. Pappalardi,Mangatt P. Biju,Erin Hugger DiFilippo,Tony Shaw,Ken Wiggall,Connie L. Erickson-Miller +10 more
TL;DR: GSK1278863 is a pyrimidinetrione-glycinamide low nanomolar inhibitor of PHDs 1–3 that stabilizes HIFα in cell lines, resulting in the production of increased levels of EPO, and is currently in phase 3 clinical trials for treatment of anemia in patients with chronic kidney disease.
Journal ArticleDOI
Rational Design, Synthesis, and SAR of a Novel Thiazolopyrimidinone Series of Selective PI3K-beta Inhibitors
Hong Lin,Mark J. Schulz,Ren Xie,Jin Zeng,Juan I. Luengo,Michael D. Squire,Rosanna Tedesco,Junya Qu,Karl F. Erhard,James F. Mack,Kaushik Raha,Ramona Plant,Cynthia M. Rominger,Jennifer L. Ariazi,Christian S. Sherk,Michael D. Schaber,Jeanelle McSurdy-Freed,Michael D. Spengler,Charles B. Davis,Mary Ann Hardwicke,Ralph A. Rivero +20 more
TL;DR: A novel thiazolopyrimidinone series of PI3K-beta selective inhibitors has been identified and provided an excellent tool compound that showed potent growth inhibition in the PTEN-deficient breast cancer cell line MDA-MB-468 under anchorage-independent conditions.